Johnson & Johnson presented significant clinical data at ASCO 2026, featuring promising results for nipocalimab and practice-changing Phase 3 outcomes in prostate cancer and myeloma. The company also announced a $1 billion acquisition of Firefly Bio to access its specialized platform for targeting KRAS-driven tumors. Furthermore, new data showed that the Talvey and Darzalex Faspro combination reduced disease progression risk by 72% in earlier-stage multiple myeloma.
